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OBJECTIVES This study was performed to test the hypothesis that tenascin-C (TN-C), an extracellular
matrix (ECM) protein with counteradhesive chemotactic and vascular growth-promoting
effects, is expressed in “arterialized” human saphenous vein grafts (SVGs).
BACKGROUND Tenascin-C is expressed in the vessel wall after vascular injury in the experimental model,
where it has been implicated in the formation of neointima. Overexpression of TN-C has also
been implicated in the development and progression of pulmonary hypertension. Saphenous
vein grafts are exposed to hemodynamic stress when interposed in the arterial circulation and
mechanical stress upregulates expression of TN-C, whereas stress-relaxation suppresses its
synthesis. We hypothesized that the hemodynamic stress of increased arterial pressure could
also induce TN-C expression in SVG.
METHODS We examined the expression of TN-C protein and mRNA in normal vein and “arterialized”
human SVG using immunohistochemistry and in situ hybridization, respectively.
RESULTS TN-C protein was not detected in control human saphenous veins; however, it was uniformly
and strongly expressed in the adventitia and media of patent human vein grafts, with minimal
or no expression in the neointima (n 5 27, 100%). In situ hybridization showed that TN-C
mRNA was not detected in the neointima, but was strongly upregulated in the adventitia and
media, corroborating immunostaining data (n 5 10, 100%). Unlike patent SVG, TN-C was
not expressed in the adventitia of occluded grafts, except for a low level of expression around
the newly formed vessels in neointima (n 5 5, 100%). Smooth muscle cell-specific staining
demonstrated that the lack of expression of TN-C in occluded vein grafts is not due to the
lack of presence of smooth muscle cells in the graft.
CONCLUSIONS These findings suggest that placement of a venous graft in the arterial system leads to
expression of TN-C, which may in turn facilitate graft remodeling. Conversely, loss of flow
and intravascular pressure, associated with vein graft occlusion, is accompanied by disappear-
ance of TN-C expression. (J Am Coll Cardiol 1999;34:871–5) © 1999 by the American
College of Cardiology
Although coronary artery bypass grafting (CABG) is an
effective therapy for patients with coronary artery disease,
about 50% of grafts close within 10 years (1,2). After the
first year, most graft closures are due to intimal hyperplasia
with or without subsequent atherosclerosis (3,4). Graft
failure is the leading cause of recurrent ischemia and need
for subsequent revascularization procedures in patients after
CABG.
Extracellular matrix (ECM) proteins play a crucial role in
the remodeling of blood vessels by affecting cell adhesion,
growth, migration, apoptosis and morphology (5). One
matrix protein that has been implicated in tissue remodeling
is tenascin-C (TN-C). It is not generally found in normal
adult tissue but is strongly expressed in a site-restricted
fashion during both embryogenesis and wound healing. It is
believed that TN-C is involved in cell growth, migration,
differentiation and apoptosis, processes that are important in
wound healing (6). Tenascin-C is not found in normal
arteries, but it is highly expressed in balloon-injured arteries
(7). We have demonstrated that the expression of TN-C in
aortic smooth smooth muscle cells (SMCs) is regulated by
chemotactic factors (8). Furthermore, TN-C blocks adhe-
sion of human and rat SMCs to fibronectin, and mediates
migration of SMCs (9,10). There is no information about
the expression and role of TN-C in human vein grafts.
Consequently, the goal of this study was to establish the
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spatial distribution of TN-C in a series of excised patent and
occluded human vein grafts, as a first step in assessing the
potential role of TN-C in saphenous vein graft (SVG)
remodeling and closure.
The normal saphenous vein consists of three layers (4).
The normal intima is thin, overlying an often incomplete
internal elastic lamina. The media is more heterogeneous
than that of arteries of similar size, consisting of a mixture
of mostly circularly arranged SMCs, ECM proteins and
some elastic fibers with no distinct external elastic lamina.
The adventitia is composed of abundant amounts of colla-
gen with a lesser amount of elastic fibers. The presence of
bundles of adventitial SMCs, not present in arteries of
similar size, is conspicuous in the veins.
With aging, presumably related to hydrostatic pressure,
saphenous veins in the lower extremities may develop
intimal hyperplasia composed of primarily SMCs and col-
lagen, medial hypertrophy and in some cases dilation
(varicose veins).
When implanted into the arterial circulation, the intimal
proliferation and thickening is accelerated, a more distinct
internal elastic lamina becomes apparent, with medial fibro-
sis, hypertrophy and adventitial fibrosis. Lipid deposition,
inflammatory cell infiltration and calcification of the intima
are often present as well. The remodeling and atheroma
formation are responsible for the veins assuming character-
istics of arteries, hence the term “arterialization.”
MATERIALS AND METHODS
SVGs. Thirty-two human vein grafts were obtained from
12 patients who underwent heart transplantation. As a
control for vein tissue, we used eight sections from eight
human saphenous veins obtained during coronary bypass
surgery that were not used for coronary bypass. These
specimens were fixed in 10% buffered formalin for 4 h and
embedded in paraffin. The HXB 1005 polyclonal antibodies
to purified human TN-C were a gift from Dr. H. P.
Erickson (Duke University). Dr. Erickson has established
the specificity of these antibodies. We further confirmed the
specificity of the antibodies by Western blot using condi-
tioned media derived from cultured SMCs. These antibod-
ies are highly specific and do not cross-react with other
matrix proteins found in the aorta, including fibronectin,
vitronectin, collagen and laminin (9). Cell proliferation was
evaluated in eight cases by immunohistochemistry using
anti-PCNA antibodies (Dako Corporation, Carpinteria,
California).
Identity of the cells. Antibodies used included SM-1
directed to smooth muscle a-actin, smooth muscle (SM)
myosin heavy chain, h-caldesmon, desmin and vimentin (all
from Sigma Chemical Co., St. Louis, Missouri). These
antibodies were used at 1:50 dilution as recommended by
the manufacturer. The anti-caldesmon antibodies have been
shown to be specific for 120- to 150-kDa h-caldesmon and
do not cross-react with skeletal or cardiac muscle or with
70-kDa nonmuscle caldesmon. The anti-desmin antibodies
cross-react with skeletal, cardiac, visceral and SMCs.
Immunohistochemistry. Staining was performed by the
avidin-biotin complex immunoperoxidase procedure.
Briefly, slides were deparaffinized and treated with H2O2 to
eliminate endogenous peroxidase activity. The sections were
incubated for 2 h with primary rabbit anti-TN-C antibody
(1:500 dilution) followed by repeated wash and 30-min
incubation with biotin-conjugated goat anti-rabbit IgG
(Dako) secondary antibodies. After washing, slides were
incubated with 2.5 mg/ml streptavidin-peroxidase (Dako)
for 30 min, developed with substrate, 3% amino-4-
ethylcarbazolein N,N dimethylformamide (AEC) (Dako),
counterstained with hematoxylin for 30 s and coverslipped.
The preimmune serum was used as negative control.
Riboprobe preparation and in situ hybridization. In situ
hybridization was performed essentially as described (11)
with some modification. We generated human TN-C
cDNA corresponding to the fibrinogen-like domain by
subcloning it into pBluescript. We also generated a dig-
oxigenin riboprobe, instead of radioactive probe, using
DIG RNA Labeling Kit (Boehringer Mannheim, Mann-
heim, Germany) as recommended by the manufacturer.
Tissue sections were deparaffinized, washed, prehybridized,
hybridized and digested with RNase, and alkaline
phosphatase-conjugated anti-digoxigenin antibody was
used to detect the probe. Once the color intensity was
attained, the reaction was stopped, and specimens were
counterstained with Fast Green (Sigma).
Statistical analysis. The statistical analysis of the sections
was performed using chi-square test. A p value , 0.05 was
considered statistically significant.
RESULTS
In total, 60 different segments from 32 different human vein
grafts were studied. Compared with control veins, all vein
grafts showed more intimal hyperplasia. The magnitude of
intimal hyperplasia varied greatly among the vein grafts.
Overall, 14 vessel segments were classified as mildly dis-
eased. All of these segments showed mild intimal prolifer-
ation and contained no atheroma. A total of 38 vessels were
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moderately diseased and eight contained atheroma. Eight
vessel segments were occluded.
Tenascin-C was not detected in control human veins (Fig.
1C). It was strongly expressed in patent vein grafts (Fig. 1A).
All 50 (100%) patent vein graft segments expressed TN-C.
Spatially, TN-C was concentrated in the adventitial and
medial ECM, but the neointima did not stain. There was
inconsistent staining of the endothelial cells. In contrast to
patent grafts, TN-C either was not detected or only weakly
expressed in eight out of eight (100%) occluded graft segments
(Fig. 1B). The overall data are summarized in Table 1.
In situ hybridization was used to determine whether the
distribution of TN-C protein (Fig. 2A) correlated with the
mRNA. Tenascin-C mRNA was detected predominantly in
the ECM of adventitial and medial cells (Fig. 2B). The
neointima was uniformly negative. This pattern of expres-
sion was similar in all sections examined (100%). These data
show a close correlation between the distribution of TN-C
protein and mRNA, suggesting that TN-C remains close to
the source of synthesis and does not diffuse away.
Because TN-C has been implicated as a comitogen for
SMCs (12), we compared its expression pattern with
PCNA-positive cells. PCNA positivity was found through-
out the patent vein graft in all sections, concentrated
primarily in the adventitia and neointima (Fig. 3A). PCNA
positivity was found infrequently in the medial layer of the
grafted segment. This suggests a high level of proliferation
of adventitial and neointimal cells. We did not find a
correlation between TN-C expression and PCNA positiv-
ity.
In contrast to patent veins, occluded veins stained weakly
with anti-TN-C antibodies (Fig. 1B). This relative lack of
expression cannot be explained by acellularity of the oc-
cluded veins, as cell-specific staining of serial sections
showed that the occluded veins were highly cellular. Smooth
muscle-specific myosin heavy chain antibodies strongly
stained neointima and adventitia, whereas media stained
weakly (Fig. 4A). The h-caldesmon antibodies consistently
stained SMC bundles found in the adventitia and neointi-
mal cells, but stained medial cells weakly (Fig. 4B). Staining
Figure 1. Comparison of TN-C expression in the control saphe-
nous vein, patent and occluded vein graft. (A) TN-C was strongly
expressed around the muscle bundles in the adventitia (a) and
media (m) of the patent vein graft (red), but not in the neointima
(n). Inset shows higher magnification of the adventitia and media.
(B) TN-C either was not detected or was weakly expressed in
occluded graft segments. (C) Lack of detectable expression of
TN-C in control veins. Magnifications: A and B, 103 C, 303,
reduced by 65%.
Table 1. The Expression of Tenascin-C in the Patent and
Occluded Human Vein Grafts
Control
Vein
Patent
Vein Graft
p
Value
Positive stain n 5 0 n 5 52
Negative stain/
weak positive
n 5 8 n 5 0
, 0.005
Occluded
Vein Graft
Patent
Vein Graft
p
Value
Positive stain n 5 0 n 5 52
Negative stain/
weak positive
n 5 8 n 5 0
, 0.005
n is the number of segments stained for tenascin-C. The statistical analysis of the
sections was performed using chi-square test. A p value , 0.05 was considered
statistically significant.
Figure 2. Representative photomicrograph of in situ hybridization
with digoxigenin-labeled TN-C cRNA probe. Immunostaining of
the serial section with anti-TN-C antibodies and antisense probe
shows that the distribution of TN-C protein (A) correlates with
the mRNA (B). Tenascin-C protein (red) and mRNA (dark blue)
was detected predominantly in the adventitia (a) and media (m).
The neointima (n) was uniformly negative. Magnification: 303,
reduced by 59%.
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pattern with anti-desmin antibodies was similar to
h-caldesmon (Fig. 4D). Anti-SM-a-actin (Fig. 4C)
strongly stained SM bundles found in the adventitia and
neointimal cells.
A similar staining pattern was found in the patent vein
grafts. Anti-myosin (Fig. 5A), anti-caldesmon (Fig. 5B),
anti-desmin (Fig. 5C) and anti-SM-a-actin (Fig. 5D)
strongly stained SM bundles found in the adventitia and
neointimal cells. We consistently observed that neointima
and adventitial cells, particularly SM bundles, stained with
the SM-a-actin, desmin and caldesmon antibodies, whereas
medial cells were either weakly stained or were negative.
Based on this staining pattern, we concluded that TN-C is
not uniformly expressed by SMCs of the patent vein graft
and that its expression by adventitial and medial cells, either
SMCs or myofibroblasts or both, is subject to a different
regulatory control than neointimal cells.
DISCUSSION
This report provides the first description of TN-C expres-
sion in human vein grafts. We found two novel features of
TN-C expression. First, although TN-C was not expressed
in control human veins, it was highly expressed in “arteri-
alized” veins in a distinct spatial pattern. Tenascin-C
expression was highly concentrated in the adventitia and
media, but was absent from the neointima of the vein graft.
We have previously demonstrated that TN-C blocks adhe-
sion of aortic SMCs to fibronectin (9). Recently, we have
demonstrated that TN-C facilitates migration of aortic
SMCs (10). Consequently, we propose that the expression
of TN-C in the SVGB adventitia and media most likely
reduces interaction of cells with their surrounding matrix,
promoting their migration.
In addition to its effect on SMC migration, TN-C may
affect expression of genes that are important in vascular
remodeling. For example, fibroblasts plated on a mixture of
fibronectin and TN-C, but not fibronectin alone, showed an
increase in the synthesis of four gene products: collagenase,
stromelysin, a 92-kDa gelatinase and c-fos (13). The effect
on metalloproteinase expression is reversed in the presence
of a monoclonal antibody that reacts with the seventh and
eight fibronectin type III repeats, suggesting that these
changes in gene expression may be related to the counter-
adhesive activity of TN-C. Thus, we also hypothesize that
the expression of TN-C serves to create a microenviron-
ment that promotes “arterialization” and remodeling of vein
grafts by promoting expression of metalloproteinases.
Figure 4. Cell-specific staining of the occluded vein graft. Staining of serial sections, with antibodies specific to myosin heavy chain (A),
h-caldesmon (B), a-actin (C) and desmin (D), shows that the occluded veins were highly cellular. All are shown as red reaction product.
Magnifications: A, B, C, 103; D, 153, reduced by 65%.
Figure 3. Cell proliferation and TN-C expression in the patent vein
graft. The pattern of cell proliferation was compared with the
expression of TN-C. (A) PCNA labeling of vein graft (brown
reaction product indicated with arrowhead) shows numerous PCNA-
positive cells in the adventitia (a) and neointima (n). (B) TN-C
expression (red) was concentrated in the adventitia (a) and media (m)
but not found in the neointima (n). Magnification: 303, reduced by
65%.
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The second novel finding of our study is the correlation
between TN-C expression and patency of the vein graft.
This suggests that TN-C expression may be in part regu-
lated by mechanical strain. There is a substantial body of
data to support this hypothesis. Cells bind to ECM via
specific cell surface receptors that activate signal transduc-
tion pathways within the cells and may act as mechano-
chemical transducers (14). For example, bone cells remodel
their matrix and reorient bone trabeculae in response to
mechanical strain (15). Fibroblasts attached to a collagen
matrix under mechanical strain produce more of the ECM
protein TN-C and collagen XII than cells in a relaxed
matrix (16). In vivo, both TN-C and collagen are specifi-
cally expressed in locations where mechanical strain is high.
In addition, the chick TN-C gene promoter contains a
novel cis-acting, strain-responsive element that causes en-
hanced transcription in cells attached to a strained collagen
matrix. It is possible, therefore, that connective tissue cells,
either SMCs or myofibroblasts, or both, sense force vectors
in their ECM environment and react to altered mechanical
needs by regulating the transcription of specific ECM
genes. In blood vessels, chronic arterial hypertension leads
to proliferation and hypertrophy of SMCs in blood vessel
walls (17), possibly due to the synthesis of PDGF-BB after
activation of a cis-acting element found in its promoter (18).
We hypothesize that strain-induced and growth factor-
induced remodeling of vein grafts is initiated, in part, by the
induction of TN-C, which in turn, promotes SMC migra-
tion (10) and growth (12), leading to the formation of
neointima and “arterialization” of the vein graft.
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